Research and Clinical Trials

A Phase I - II Study of the Safety and Efficacy of a True Human Antibody
Brief Description  
Staphylococcal bacteremia is a serious infection that despite intravenous antibiotic therapy still has a mortality of 20 to 40%. Previous attemopts to augment antibiotic therapy with passive immunization strategies have been met with limited success, due to the presence of the virulence factor, Staphylococcal Protein A (SpA). SpA binds the Fc region of immunoglobulins, effectively neutralizing them, which interferes with complement activation and phagocytosis.
Who may be Eligible  
Patients =18 years of age who have Bacteremia Due to Staphylococcus Aureus
Start Date  
IRB Number  
Principal Investigator  
Huynh, Toan
Contact Name  

For More Information, Contact   Julia  Raddatz , MS
Phone:  (074) 355-8287  Fax:  (704) 355-7730 
Address:  Carolinas HealthCare System
1000 Blythe Blvd, MEB 202
Charlotte, NC 28203